ClinicalTrials.gg
RecruitingNCT07569653Updated Jun 1, 2026

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

A Phase 4 interventional study of CMV-Specific T-cell Guided Letermovir Discontinuation and Standard Letermovir Prophylaxis in Cytomegalovirus Infections, Cytomegalovirus Disease and Hematopoietic Stem Cell Transplantation, sponsored by WeiShi. Recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by WeiShi · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cytomegalovirus Infections with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cytomegalovirus Infections · China.

Planned enrollment
2nd of 11
120 · median 80
Started
2025
with 1 other
Phase 4
2 of 23
1 open now
Registered
22nd of 23
by date

Among the 23 studies in Cytomegalovirus Infections with a site in China, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 22nd registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

8 of the 23 studies in Cytomegalovirus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cytomegalovirus Infections with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus [CMV] infection) based on the recovery of the patient's own immune system.

Cytomegalovirus (CMV) is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, Letermovir is typically given as a standard prevention for about 100 days post-transplant. However, some patients may recover their CMV-specific immunity earlier, while others may need longer protection.

In this study, researchers will use a dynamic monitoring technology (QuantiFERON-CMV) to detect the level of CMV-specific T-cells in patients. Participants will be randomly assigned to either the experimental group or the control group:

Experimental Group: Letermovir discontinuation will be guided by T-cell recovery. If the test shows that the patient's CMV-specific T-cells have recovered, Letermovir may be stopped earlier than the standard 100 days.

Control Group: Patients will receive the standard Letermovir prophylaxis for approximately 100 days, regardless of T-cell status.

The study aims to determine if this immune-guided strategy can effectively prevent CMV infection while potentially reducing the duration of medication and associated costs, without increasing the risk of CMV disease.

03

Conditions studied

  • Cytomegalovirus Infections
  • Cytomegalovirus Disease
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Recipients of hematopoietic stem cell transplantation (allo-HSCT).
  2. CMV serostatus of the recipient is positive (R+).
  3. Aged 18 years or older.
  4. Expected survival > 6 months.
  5. Provision of signed .

Exclusion criteria

Exclusion Criteria:

  • 1.Active CMV infection or CMV disease at the time of screening.

    2.Known to Letermovir or its .

    3.Severe hepatic or renal impairment.

    4.Pregnant or breastfeeding women.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental (T-cell Guided Group)

    Drug: CMV-Specific T-cell Guided Letermovir Discontinuation

  • Active comparator
    Active Comparator (Standard Prophylaxis Group)

    Drug: Standard Letermovir Prophylaxis

Interventions

  • DrugCMV-Specific T-cell Guided Letermovir Discontinuation

    Patients receive Letermovir prophylaxis (480 mg/day orally or IV) according to the standard protocol until approximately 100 days post-transplantation, regardless of T-cell recovery status.

  • DrugStandard Letermovir Prophylaxis

    Patients receive Letermovir prophylaxis (480 mg/day orally or IV) according to the standard protocol until approximately 100 days post-transplantation, regardless of T-cell recovery status.

06

What researchers measure

Primary outcomes

  1. Incidence of Clinically Significant CMV Infection (CS-CMVi)

    The percentage of participants who develop clinically significant CMV infection, defined as CMV DNAemia requiring preemptive antiviral therapy (PET) according to institutional guidelines (e.g., two consecutive positive results or a single viral load ≥ 500 copies/mL) or the occurrence of CMV disease (e.g., CMV pneumonia, enteritis, or retinitis).

    Time frame: Through 200 days post-transplantation

Secondary outcomes

  1. Duration of Letermovir Prophylaxis

    The total number of days each participant received Letermovir prophylaxis from the start of treatment (between Day 0 and Day 28 post-HSCT) until the end of the intervention (up to 200 days). This measure will compare the median duration of medication between the experimental arm (T-cell guided) and the control arm (standard 200-day prophylaxis) to evaluate the reduction in drug exposure.

    Time frame: Through 200 days post-transplantation

07

Study locations

1 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 6, 2026
StartActual
Oct 30, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569653
Lead sponsor
WeiShi
Responsible party
WeiShi (Chief Physician, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Sponsor-investigator
First posted
May 6, 2026
Start date
Oct 30, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

wei MD, PhD
Contact
shiwei076@hust.edu.cn
+86 027-85726003

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion